McKesson Ventures’ Dave Schulte Named One of Healthcare’s Top 25 Investors
McKesson Ventures Managing Director Dave Schulte has been recognized by GrowthCap as one of the top 25 healthcare investors for 2023. This award acknowledges healthcare investors who have demonstrated high levels of sustained investment performance and who are recognized as leaders by portfolio company CEOs, industry peers, and colleagues.
For 20 years, Schulte has been investing in innovative healthcare technology and services businesses focused on improving data insights, health outcomes, and access to care. He joined McKesson Ventures as a managing director in 2014 after 10 years leading Kaiser Permanente Ventures. He took the helm at McKesson Ventures in 2020 when Tom Rodgers left the role to accept a position as executive vice president and chief strategy officer at McKesson, and now leads one of the most respected and diverse investment teams in healthcare venture.
“This recognition underscores the success of our fund and appreciation for the value of partnering with McKesson Ventures,” Schulte said. “I am proud of the team we have built, the entrepreneurs we have supported, and the impact that we have had on healthcare innovation. We have never been more optimistic about the potential for entrepreneurial companies to advance health outcomes and our ability to help them succeed.”
During his tenure at McKesson Ventures, Schulte has helped build out one of the industry’s strongest pharma services portfolios, which include his investments in Komodo Health, Shyft Analytics (acquired by Medidata), and Saama. He has also led investments in several other category-defining businesses in value-based care, including Aledade and Landmark Health (acquired by Optum).
Schulte began his career in investment banking at JP Morgan, Piper Jaffray, and UBS. He is a graduate of St. John’s University and received a Master of Public Policy from the Harvard Kennedy School.
Read the original press release here.